Company Analysis
Sign in

Rocket Pharmaceuticals, Inc. (RCKT)

Nasdaq: RCKT · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2004
Full chart Alerts Compare
Grade4.5
◀ Past 5.4● Present 5.0▶ Future 3.6
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

39 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Rocket Pharmaceuticals, Inc.’s names, not what it holds today.

Patents granted
39
39 utility, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
52
since 2001, to Dec 31, 2025
Names they are printed under
4
a former name, its own name
By yearGrantedApplications published
'05'06'07'08'09'10'11'12'13'14'15'16'17'20'21
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
Under which name4 counted
Inotek Pharmaceuticals Corporation a former name
US, as the owner printed on each patent. 1 more under the same name are not counted (printed in NZ)
38 granted
40 published
Inotek Pharmaceuticals Corporation a former name
named as the applicant on its applications, in US
0 granted
8 published
Rocket Pharmaceuticals, Ltd. its own name
named as the applicant on its applications, in US
0 granted
3 published
Rocket Pharmaceuticals, Ltd. its own name
US, as the owner printed on each patent
1 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Jul 7, 202010,703,797Gene therapy vectors for treatment of Danon diseasePharmaceuticalsRocket Pharmaceuticals, Ltd.
Aug 1, 20179,718,853Anhydrous polymorphs of [(2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-YL)-3,4-dihydroxytetrahydrofuran-2-YL)] methyl nitrate and processes of preparation thereofPharmaceuticalsInotek Pharmaceuticals Corporation
Dec 20, 20169,522,160Ophthalmic formulationsPharmaceuticalsInotek Pharmaceuticals Corporation
Jun 21, 20169,370,530Combination, kit and method of reducing intraocular pressurePharmaceuticalsInotek Pharmaceuticals Corporation
Mar 22, 20169,289,383Method of reducing intraocular pressure in humansPharmaceuticalsInotek Pharmaceuticals Corporation
Mar 8, 20169,278,991Anhydrous polymorphs of [(2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereofPharmaceuticalsInotek Pharmaceuticals Corporation
Nov 25, 20148,895,530Method of reducing intraocular pressure in humansPharmaceuticalsInotek Pharmaceuticals Corporation
Nov 4, 20148,877,732Combination, kit and method of reducing intraocular pressurePharmaceuticalsInotek Pharmaceuticals Corporation
Dec 17, 20138,609,833Purine derivatives as adenosine A1 receptor agonists and methods of use thereofPharmaceuticalsInotek Pharmaceuticals Corporation
Aug 6, 20138,501,708Adenosine compounds and their use thereofPharmaceuticalsInotek Pharmaceuticals Corporation
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Sep 23, 20212021/0290685METHODS FOR GENE MODIFICATION OF HEMATOPOIETIC CELLSBiotechnologyRocket Pharmaceuticals, Ltd.
Jul 29, 20212021/0230631GENE THERAPY FOR CNS DEGENERATIONBiotechnologyRocket Pharmaceuticals, Ltd. · patent 12,378,576 granted from it
May 27, 20212021/0154237COMPOSITIONS AND METHODS FOR STEM CELL TRANSPLANTPharmaceuticalsRocket Pharmaceuticals, Ltd.
May 14, 20202020/0148745GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASEPharmaceuticalsRocket Pharmaceuticals, Ltd. · patent 10,703,797 granted from it
Jun 1, 20172017/0151273OPHTHALMIC FORMULATIONSPharmaceuticalsInotek Pharmaceuticals Corporation
Feb 23, 20172017/0049799OPHTHALMIC FORMULATIONSPharmaceuticalsInotek Pharmaceuticals Corporation
Dec 22, 20162016/0367586COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSUREPharmaceuticalsInotek Pharmaceuticals Corporation
Jun 9, 20162016/0158268METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANSPharmaceuticalsInotek Pharmaceuticals Corporation
Jun 9, 20162016/0158267METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATIONPharmaceuticalsInotek Pharmaceuticals Corporation
May 19, 20162016/0137686ANHYDROUS POLYMORPHS OF [(2R,3S,4R,5R)-5-(6-(CYCLOPENTYLAMINO)-9H-PURIN-9-YL)-3,4-DIHYDROXYTETRAHYDROFURAN-2-YL)] METHYL NITRATE AND PROCESSES OF PREPARATION THEREOFPharmaceuticalsInotek Pharmaceuticals Corporation · patent 9,718,853 granted from it

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton RCKT · research, not advice